drugset / Trial / NCT00610363

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

NCT00610363

Phase 2 Completed 83 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use in preventing gout attacks in participants who had gout.

Timeline

Start
2007-11
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilonacept Protein / enzyme biologic 160 mg Subcutaneous

Indications